ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS AND HIV-1 CO-INFECTED SUBJECTS

丙型肝炎病毒和 HIV-1 合并感染受试者的抗病毒治疗

• 批准号: 7375261
• 负责人: THOMAS C MERIGAN
• 金额: $ 6.32万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375261
• 关键词: ANTIVIRAL; MANAGEMENT; HEPATITIS; VIRUS; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿ve and previously treated subjects will be enrolled.

该主题是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是针对该中心的，这不是调查人员的机构。这是一项II期，开放标签，两臂长期维护治疗研究。该试验旨在研究用钉二叶纤维I-2A（PEG-IFN）长期维持是否会降低HCV/HIV共感染受试者的肝纤维化进展速率，而HCV/HIV共感染未能达到或维持HCV负载在使用PEG-IFN Plus Plus Plus Plus Ibravirin治疗期间未能达到或保持HCV负载量以下。 HCV治疗均应纳入和先前治疗的受试者。